智通财经6月6日电，脑机接口概念股午后异动，爱朋医疗涨超10%，倍益康、诚益通、中科信息、创新 医疗、东方中科、三博脑科等跟涨。消息面上，2025年被视为中国脑机接口技术迈向临床的关键节点， 北京、上海等地已规划在2030年前完成多款侵入式产品的临床试验。 脑机接口概念股异动拉升 爱朋医疗午后涨超10% ...

Company Overview - Aipeng Medical focuses on the research, production, and sales of medical devices in pain management and nasal cavity management [1] - The company's main products include pain management products and nasal cavity management products [1] Financial Performance - For Q1 2025, Aipeng Medical reported revenue of 64.82 million yuan, a year-on-year decrease of 26.13% [1] - The net profit for the same period was -17.65 million yuan, reflecting a year-on-year decline of 1400.65% [1] - The gross profit margin stood at 61.91% [1] Market Position - Aipeng Medical's "Nose Clear" nasal care products have been the top-selling items in the nasal irrigation category on both Tmall and JD.com for nine consecutive years [1] - The brand has received several awards, including the "West Lake Award for Innovative Marketing" and recognition as a "Star Product Most Popular Among Pharmacies" [1] - "Nose Clear" has been included in the Shanghai Key Trademark Protection List, highlighting its market significance [1] Shareholder Information - As of March 31, 2025, Aipeng Medical had 20,629 shareholders, an increase of 1,752 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Valuation Metrics - Aipeng Medical's current price-to-earnings (PE) ratio (TTM) is -382.20, and the price-to-book (PB) ratio is 4.60 [2] - The total market capitalization of Aipeng Medical is 3.136 billion yuan [2]

Core Viewpoint - The establishment of the Aipeng Medical Artificial Intelligence and Brain-Computer Interface Research Institute marks a significant step in the integration of brain science and AI, aiming to drive innovation in the medical field through advanced technology [1][3]. Group 1: Research Institute and Expert Involvement - The research institute has appointed a group of experts from prestigious institutions to support Aipeng Medical in technology innovation, product implementation, and industry collaboration [3]. - The chairman of Aipeng Medical emphasized the importance of embracing the opportunities presented by AI and brain-computer interface technologies to explore new possibilities at the intersection of technology and clinical applications [3]. Group 2: Market Growth and Focus Areas - The global brain-computer interface market has grown from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13%, and is projected to reach $7.63 billion by 2029 [5]. - The research institute will focus on three main areas: pain management, anesthesia and sedation, and mental health treatment, aiming to enhance medical service quality and efficiency [5]. Group 3: Clinical Applications and Innovations - Approximately 27% of the global population suffers from sleep disorders, with nearly 300 million affected in China, highlighting the need for innovative solutions in sleep medicine [7]. - Aipeng Medical's new generation ADM anesthesia depth monitor leverages non-invasive EEG technology and AI to provide real-time monitoring and precise staging of sleep, paving the way for intelligent solutions in sleep medicine [7]. - The company is also developing brain-computer interface products for ADHD treatment, utilizing game-based interactive designs to enhance engagement and compliance among children [9]. Group 4: Long-term Technological Innovation - Aipeng Medical has a history of strategic investments in brain-computer interface technologies, including partnerships and product launches since 2019, indicating a systematic approach to this high-barrier field [13]. - The establishment of the research institute aims to bridge the gap between academia and industry, facilitating a collaborative environment for technological advancements [14][16]. - The company plans to leverage the research institute to drive long-term technological innovation and transition from a traditional medical device manufacturer to an AI-driven medical technology platform [16].

Group 1: Market Performance - The brain science sector showed strong performance on May 30, with companies like Innovation Medical and Aipeng Medical seeing significant stock price increases, with Aipeng Medical rising over 15% during trading [1][2]. Group 2: Neuralink Developments - Neuralink, Elon Musk's brain-machine interface company, completed a $600 million financing round, with a pre-financing valuation of $9 billion [3]. - Neuralink's device, Link, received "breakthrough device" designation from the FDA, aimed at helping patients with severe speech disabilities [3]. - The National Healthcare Security Administration released guidelines for pricing new neuro-system medical services, including specific pricing for invasive and non-invasive brain-machine interfaces [3]. Group 3: Institutional Insights - Brain-machine interfaces are expected to become a core technology for human-machine interaction, initially focusing on medical rehabilitation, with future applications in education, entertainment, military, and industrial sectors [4]. - The FDA's certification of Neuralink indicates a positive outlook for the clinical application of brain-machine interface devices, potentially accelerating commercialization [4]. - The establishment of a specialized pricing standard for brain-machine interface technology by the National Healthcare Security Administration addresses the challenge of rapid development versus slow implementation, creating a policy framework for pricing and quality control [4].

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-024 江苏爱朋医疗科技股份有限公司 2024年年度权益分派实施公告 2、自上述分派方案披露日至本公告日，公司股本总额未发生变化。 3、本次实施的权益分派方案与公司2024年年度股东会审议通过的分配方案及其 调整规则一致。 4、本次权益分派方案实施距离股东会审议通过的时间未超过两个月。 二、权益分派方案 公司2024年年度权益分派方案为：以公司现有总股本126,048,000股为基数，向全 体股东每10股派0.650000元人民币现金（含税；扣税后，境外机构（含QFII、RQFII） 以及持有首发前限售股的个人和证券投资基金每10股派0.585000元；持有首发后限售 股、股权激励限售股及无限售流通股的个人股息红利税实行差别化税率征收，本公司 暂不扣缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额【注】；持 有首发后限售股、股权激励限售股及无限售流通股的证券投资基金所涉红利税，对香 港投资者持有基金份额部分按10%征收，对内地投资者持有基金份额部分实行差别化 税率征收）。 - 1 - 本公司及董事会全体成员保证信息披露的内容真实、准确、 ...

Group 1: Industry Outlook - The medical device industry, particularly in pain management and upper airway management, has significant growth potential due to increasing surgical procedures and pain management needs. In 2023, there were approximately 96.39 million surgical procedures in China, with 70%-80% of postoperative patients experiencing severe pain [4][5]. - The current pain relief rate for childbirth in China is about 30%, compared to 85%-98% in developed countries, indicating substantial market potential for growth [4]. - The prevalence of allergic rhinitis in China is 17.6%, and chronic sinusitis is around 8%, suggesting a rising demand for nasal treatments [5]. Group 2: Company Performance - In 2024, the company reported total revenue of 403.80 million yuan, a decrease of 4.35% from the previous year, while net profit attributable to shareholders was 10.80 million yuan, an increase of 30.49% [6][8]. - The pain management segment generated revenue of 248.43 million yuan, reflecting a growth of 12.42%, while the upper airway management segment saw a decline of 32.61%, with revenue of 123.38 million yuan [8]. Group 3: Future Growth Strategies - The company aims to develop an ecosystem focused on single disease management, leveraging pain management and upper airway management as foundational areas while exploring innovations in brain-computer interfaces and perioperative recovery [7]. - Future initiatives include the application of artificial intelligence for product development in pain assessment, sleep diagnostics, and brain health evaluations, which are expected to drive long-term growth [7].

上海君澜律师事务所 关于江苏爱朋医疗科技股份有限公司 2024 年年度股东会的法律意见书 致：江苏爱朋医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"）等法 律、法规、规范性文件及《江苏爱朋医疗科技股份有限公司章程》（以下简称"《公 司章程》"）的规定，上海君澜律师事务所（以下简称"本所"）接受江苏爱朋 医疗科技股份有限公司（以下简称"公司"）的委托，指派本所律师出席公司2024 年年度股东会（以下简称"本次股东会"），并就本次股东会的召集、召开程序 及表决程序、表决结果等事项出具本法律意见书。 本法律意见书仅供本次股东会之目的使用。本所律师同意将本法律意见书随 公司本次股东会其他信息披露资料一并公告。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对本 次股东会所涉及的有关事项和相关文件进行了必要的核查和验证，现出具法律意 见如下： 一、 本次股东会的召集、召开程序 1.1 本次股东会由公司董事会召集。 公司董事会于 2025 年 4 月 17 日召开第三届董事会第十次会议，审议通过 了 ...

关于股东回馈活动的自愿性信息披露公告 证券代码：300753 证券简称：爱朋医疗 公告编号：2025-023 江苏爱朋医疗科技股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）自成立至今，一直耕耘 于疼痛管理、鼻腔及上气道管理细分领域用医疗器械产品，积极践行"舒适化医 疗"。为建立长效股东回报机制，答谢各位股东长期以来对公司的关心和支持，公 司决定开展"守护健康·爱朋医疗股东回馈活动"，现将活动内容公告如下： 一、参加活动的股东范围 2025年5月7日（公司2024年年度股东会登记日）15:00收市后当日在中国证券登 记结算有限责任公司登记在册的持有本公司股份1000股（含）以上的股东。 二、活动具体内容 为回馈长期以来支持公司的投资者，本次活动期间内符合条件的股东可参与如 下活动： 2025年5月7日收市后登记在册的持有本公司股份1000股（含）以上的股东可免 费领取诺斯清生理性海水鼻腔护理喷雾器儿童装1瓶及小诺护眼喷雾1瓶。 - 1 - 三、活动登记时间 2025年5月13日至2025年5月22日 ...

江苏爱朋医疗科技股份有限公司 2024年年度股东会决议公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更、否决议案的情形； 证券代码：300753 证券简称：爱朋医疗 公告编号：2025-022 2、本次股东会未涉及变更前次股东会决议的情形； 3、本次股东会采取现场投票与网络投票相结合的方式召开。 一、会议的召开情况 1、会议召开的时间 （1）现场会议召开时间为：2025年5月13日（星期二）15:00。 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025年5月13日9:15至9:25，9:30至11:30，13:00至15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为：2025年5月13日9:15至15:00。 2、现场会议召开地点：上海市闵行区联航路1188号3号楼公司会议室。 3、会议表决方式：现场表决与网络投票相结合的方式。 4、会议召集人：江苏爱朋医疗科技股份有限公司董事会。 5、会议主持人：董事长王凝宇先生。 6、会议召开的合法、合规性：本次股东会会议召开符合《中 ...

Core Viewpoint - The human brain engineering sector experienced a slight increase of 0.47% on May 13, with a total capital outflow of 592.5 million [1] Group 1: Market Performance - The number of stocks that increased in value was 12, while 11 stocks saw a decline [1] - The top-performing stocks in the sector included Chengyitong (up 5.7%), Saily Medical (up 4.66%), and Aipeng Medical (up 3.6%) [1] - The stocks with the largest declines included *ST Shengxun (down 3.69%), ST Huaton (down 3.37%), and Yanshan Technology (down 2.51%) [1] Group 2: Capital Flow - The net capital inflow for the top-performing stock Chengyitong was 3.02 million, representing a net capital ratio of 8.44% [1] - Saily Medical had a net capital inflow of 31.18 million, with a net capital ratio of 9.10% [1] - In contrast, stocks like Lepu Medical and Keda Xunfei experienced net capital outflows of 0.75 million and 0.06 million, respectively [1]